IP Library Granted Patent US 9,206,426
Granted Patent B2
US 9,206,426 · App. 13/582,921 · Granted Dec 8, 2015

Inhibitory RNAs to RNA binding proteins hnRNPA1, hnRNPA2 and PTB and uses thereof

Inventors: James L. Manley (Greenlawn, NY); Mo Chen (New York, NY); Charles David (New York, NY); Jian Zhang (New York, NY)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
C12N15/1137A61K31/713A61K31/7105C12N15/113C12N2310/14C12N2310/531C12N2320/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,206,426
App. No.
13/582,921
Granted
Dec 8, 2015
Kind
B2
Abstract

Provided herein are methods to reduce or slow down cell growth, for example in a cancer cell comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB. Provided are methods to identify agents which reduce the levels of hnRNPA1, hnRNPA2 or PTB. Provided are methods to identify agents which increase ratio of PKM1/PKM2 proteins, or reduce PKM2 levels, or increase PKM1 levels.

Claims (15)

1. A method to reduce cell growth of a cancer cell comprising contacting a cancer cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63.

2. A method to treat cancer comprising administering to a subject in need thereof an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB mRNAs, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63.

3. A method to treat cancer comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63.

4. A method to reduce the levels of RNA binding proteins hnRNPA1, hnRNPA2 and PTB in a cell comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63.

5. A method to reduce the amount of hnRNPA1, hnRNPA2 and PTB protein bound to pyruvate kinase pre-mRNA in a cell, comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63.

6. A method to reduce levels of PKM2 RNA or protein in a cell, comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63.

7. A method to increase levels of PKM1 RNA or protein in a cell, comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63.

8. A method to reduce the ratio of PKM2/PKM1 RNA or protein in a cell, comprising contacting a cell with an effective amount of a combination of inhibitory RNA molecules targeting hnRNPA1, hnRNPA2 and PTB, wherein the inhibitory RNA molecule targeting hnRNPA1 comprises SEQ ID NO: 9 or is encoded by SEQ ID NO: 64, the inhibitory RNA molecule targeting hnRNPA2 comprises SEQ ID NO: 10 or is encoded by SEQ ID NO: 65, and the inhibitory RNA molecule targeting PTB comprises SEQ ID NO: 11 or is encoded by SEQ ID NO: 63.

9. The method of any of claims 1 - 8 , wherein the inhibitory RNA molecule, which targets hnRNPA1, hnRNPA2 or PTB mRNAs is a siRNA.

10. The method of any of claims 1 - 8 , wherein the inhibitory RNA molecule, which targets hnRNPA1, hnRNPA2 or PTB mRNAs is a shRNA.

11. The method of claim 10 , wherein the shRNA is comprised in an RNAi expression vector.

12. The method of any of claims 4 - 8 , wherein the cell is a cancer cell.

13. The method of claim 12 , wherein the cancer cell is brain tumor cell, a glioma tumor cell, or a breast cancer cell.

14. The method of any of claims 4 - 8 wherein the cell expresses PKM2.

15. The method of any of claims 1 - 8 , wherein SEQ ID NOs: 9, 10 and 11 are the sense strand sequence of the inhibitory RNA molecule.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 25, 2015
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035280/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2013
From: MANLEY, JAMES L.; CHEN, MO; DAVID, CHARLES; ZHANG, JIAN
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 030028/0350 →
Continuity (2)
Provisional Application 61311038 · Mar 5, 2010
Related Publication 20130203835A1 · Aug 8, 2013